Kyprolis OverviewCarfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomi...
Read more Kyprolis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Carfilzomib
Recent Kyprolis Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 60mg
- Powder: 10mg/vial, 30mg/vial, 60mg/vial
NDC Database Records for Kyprolis: (3 results)Sorted by National Drug Code
- 76075-101 Kyprolis 60 mg/30ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.
- 76075-102 Kyprolis 30 mg/15ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.
- 76075-103 Kyprolis 10 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Onyx Pharmaceuticals, Inc.